Monitoring drug ototoxicity with distorsion products;Monitorizacion de la ototoxicidad por farmacos con productos de distorsion

Acta Otorrinolaringologica Espanola

Volumn 51, Issue 5, 2000, Pages 387-395

  Orts Alborch, M ^a   Morant Ventura, A ^a   Garcia Callejo, J ^a   Ferrer Baixauli, F ^a   Martinez Beneito, M P ^a   Marco Algarra, J ^a  

^a NONE   (Spain)

Author keywords

Distortion products; Otoacoustic emissions; Ototoxicity; Tobramycin

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; AUDIOMETRY; CLINICAL ARTICLE; CONTROLLED STUDY; DISTORTION PRODUCT OTOACOUSTIC EMISSION; DRUG INDUCED DISEASE; DRUG MONITORING; FEMALE; HEARING LOSS; HUMAN; MALE; OTOACOUSTIC EMISSION; OTOTOXICITY; PERCEPTION DEAFNESS; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; METHODOLOGY; MIDDLE AGED; PURE TONE AUDIOMETRY; SPONTANEOUS OTOACOUSTIC EMISSION;

ADULT; ANTI-BACTERIAL AGENTS; AUDIOMETRY, PURE-TONE; FEMALE; HEARING LOSS, SENSORINEURAL; HUMANS; MALE; MIDDLE AGED; OTOACOUSTIC EMISSIONS, SPONTANEOUS; TOBRAMYCIN;

EID: 0033841792     PISSN: 00016519     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Relationships between ototoxicities and chemical structures of ototoxic drags
2. L'ototoxicite: Donnees experimentales et implications cliniques
3. Bases bioquimicas de la ototoxicidad de aminoglucosidos
4. Gentamicin uptake by cochlear hair cells precedes hearing impairment during chronic treatment
5. Bases fisiopatologicas de la ototoxicidad inducida por aminoglucosidos
6. Aminoglucosidos y espectinomicina: Aminociclitoles
7. Hair cell regeneration after streptomycin toxicity in the avian vestibular epithelium
8. The incidence of aminoglycoside antibiotic-induced hearing loss
9. Ototoxic antibiotics: A review
10. Clinical monitoring using otoacoustic emissions
11. Distortion product emissions in humans. II. Relations to acoustic immittance and stimulus frequency and spontaneous otoacoustic emissions in normally hearing subjects
12. Clinical significance of relative probe-tone levels of distortion product otoacoustic emissions
13. Distortion product otoacoustic emissions in kanamycin treated guinea pig cochlea
14. Evaluation of TEOAE and DPOAE measurements for the assessment of auditory thresholds in sensorineural hearing loss
15. Comparison of distortion product OAE generation between a patient group requiring frequent gentamicin therapy and control subjects
16. Frequency specificity of human distortion product otoacoustic emissions
17. Clinical testing of distortion-product otoacoustic emission
18. Variation of distortion product otoacoustic emissions with furosemide injection
19. Dependence of distortion product otoacoustic emissions on primary levels in normal and impaired ears. II. Asymmetry in L1, L2 space
20. Fine structure of the 2f1-f2 acoustic distortion products: Effects of primary level and frequency ratios
21. Acoustic distortion products can be used for monitor the effects of chronic gentamicin treatment
22. Clinical monitoring using otoacoustic emissions
23. Kanamycin depletes cochlear polyamines in the developing rat
24. Evaluation of heating loss bymeans of inner ear acoustic emission in neonates treated with aminoglycoside
25. Parametros de normalidad de los productos de distorsion
26. Productos dedistorsion acustica. Registros en sujetos normooyentes y con hipoacusia neurosensorial
27. Auditory threshold evaluation by distortion-product otoacoustic emissions using decision support system
28. Distortion product otoacoustic emission test of sensorineural hearing loss: Performance regarding sensitivity, specificity and receiver operating characteristics